‘I’d go to a family function and not talk to anyone’: the social impact of hearing loss

Alan Edwards can still remember the day he heard clearly for the first time. “It was an overwhelming sense of calm,” Edwards says, remembering sitting on a park bench and laughing as he enjoyed the sounds he’d never heard before. Alan Edwards found himself feeling isolated when his hearing deteriorated. “It was really fascinating and amazing.” Having struggled with genetic, […]

Read more

Hearing Loss Linked to Subjective Cognitive Function Decline

FRIDAY, Feb. 1, 2019 — For older men, hearing loss is associated with subjective cognitive function (SCF) decline, according to a study published online Jan. 29 in Alzheimer’s & Dementia. Sharon G. Curhan, M.D., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues conducted a longitudinal study from 2008 to 2016 involving 10,107 men aged 62 […]

Read more

Opioids Offer Small Improvement in Pain, Physical Function

TUESDAY, Dec. 18, 2018 — Opioid use is associated with small improvements in pain and physical functioning in patients with chronic noncancer pain, according to research published in the Dec. 18 issue of the Journal of the American Medical Association. Jason W. Busse, Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues conducted a systematic review of randomized clinical […]

Read more

Study shows in older people, type 2 diabetes is associated with a decline in brain function over five years

New research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) shows that in older people living in the community, type 2 diabetes (T2D) is associated with a decline in verbal memory and fluency over 5 years. However, contrary to previous studies, the decrease in brain volume often found in older people with T2D […]

Read more

Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

NEW YORK & INDIANAPOLIS–(BUSINESS WIRE October 23, 2018 )–Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients with osteoarthritis (OA) pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, demonstrating […]

Read more